Sovtech AU Launches in New Zealand, Working with Cure Kids to Deliver Cybersecurity Solutions with a Social Impact
Auckland, New Zealand — Sovtech, a leading Australian cybersecurity firm, is proud to announce its official launch in New Zealand this October, marking a new chapter in its expansion across the Tasman.
Known for its innovative ‘profit for purpose’ business model, Sovtech combines cutting-edge cybersecurity solutions with a strong social mission, including partnerships with significant causes such as Cure Kids – a leading charity dedicated to improving child health in New Zealand.
As part of the New Zealand launch, Sovtech’s Founder and Director, Neil Templeman, will be visiting Auckland on 15 and 16 October to meet with clients, partners, and government officials. Templeman brings a personal connection to New Zealand, having lived here for seven years. His goal is to establish a local presence, creating new jobs and building a robust team to serve New Zealand businesses.
“Launching in New Zealand has been driven by strong demand from customers and our partners. We see a great opportunity to help businesses here enhance their cybersecurity posture while making a positive social impact and we have recently signed our first contract in NZ with a large enterprise customer,” says Templeman.
Sovtech’s unique approach to cybersecurity sets it apart from other providers. The company offers services such as advanced email security, data protection and third-party risk management, but with a difference – profits are reinvested into causes that matter. In Australia, Sovtech has supported First Nations health and education initiatives, and with its New Zealand expansion, it has chosen to align with Cure Kids, a charity focused on funding medical research to improve the health of children.
Cure Kids is enthusiastic about this collaboration. Brendon Pongia, Head of Engagement, commented, “We are excited to have the support of Sovtech, an organisation with a strong social mission and a shared commitment to improving the health of children in New Zealand.”
By launching in New Zealand, Sovtech aims to create a lasting social impact while providing the country’s businesses with industry-leading cybersecurity solutions. Its goal is to offer both private and public sector organisations the tools they need to improve their cyber resilience, while simultaneously contributing to a broader societal mission.
“We believe technology should be a force for good, creating ripple effects that transcend borders and generations,” adds Templeman. “With our Procurement for Purpose model, New Zealand businesses have a unique opportunity to strengthen their security while driving meaningful change.”
Sovtech’s launch in New Zealand is more than just business – it’s about community, sustainability, and making a difference where it counts.
Media Contact: Neil Templeman
Founder & Director, Sovtech
Neil_templeman@sovtechnz.com
T: 00 61 419 172 445
www.sovtechnz.com
Neil Templeman will be available for interviews during his visit to New Zealand on 15-16 October. To schedule a meeting or interview, please contact him directly at the number above.
About Sovtech:
Sovtech is a cybersecurity provider offering comprehensive solutions to help businesses safeguard against modern threats. Their profit for purpose model reinvests profits into social causes, aligning technology with positive global change. https://sovtech.com.au/
About Cure Kids:
Cure Kids is New Zealand’s largest charitable funder of child health research committed to finding better treatments and preventative strategies for a wide range of serious child health conditions. Cure Kids has invested more than $65 million in New Zealand research since it formed over 50 years ago, which has helped to shape and vastly improve the way children who live with serious diseases and health conditions are diagnosed and treated. Cure Kids is currently funding around $8 million in child health research across 60+ projects. Red Nose Day is their biggest annual fundraising campaign and makes a significant contribution to this work. For more information visit: www.curekids.org.nz
Introducing NEW Selaks Origins Breeze 5%
Selaks, a pioneer in New Zealand’s wine industry, proudly unveils Selaks Origins Breeze 5%, a revolutionary addition to its portfolio.
Launching this August, Selaks Origins Breeze 5% makes its timely debut following Dry July, pioneering Selak’s first ever 5% alcohol offering in New Zealand. Each bottle promises an easy-drinking experience with just 3 standard drinks per 750ml bottle at 5% ABV.
Research consistently indicates a growing demand for lower-alcohol beverages. Consumers are increasingly mindful of their alcohol intake and are actively seeking options that allow them to enjoy wine in moderation. This shift reflects a broader cultural movement in New Zealand towards more responsible drinking habits.
The Origins Breeze range uses the Piquette method, a traditional technique originating from France. Piquette is made by rescuing already pressed winemaking grapes and giving them a second squeeze, resulting in a refreshing range that includes a crisp Piquette from Marlborough Sauvignon Blanc, a summer berry-infused Piquette Rosé, and a vibrant Piquette from Pinot Gris.
“Utilizing the traditional Piquette method, we’ve crafted fruit wines that not only minimize waste but also maximize the vibrant fruit flavors that define our fruit wines.” said David Edmonds, Chief Winemaker at Selaks.
Crafted with innovation and waste reduction in mind, this range caters to wine enthusiasts and health-conscious consumers alike, seeking a flavourful, lighter option without compromising on taste.
“At Selaks, we’re excited to introduce the Origins Breeze 5% range, a testament to our commitment to quality and innovation,” added Edmonds.
“We’ve focused on creating a product that captures the bright, fresh characteristics of our fruit, appealing to a broad spectrum of consumers,”
Selaks Origins Breeze 5% is poised to redefine expectations of lower-alcohol fruit wines, offering a delicious choice for any occasion.
About Selaks: 90 Years of Winemaking
Founded with a rich heritage, Selaks is celebrated for crafting exceptional New Zealand wines that honor tradition while embracing innovation. Since Marino Selak arrived from Croatia in 1906, he and his nephew began creating wines that have become favorites across New Zealand, marking the start of Selaks’ legacy of excellence in winemaking.
From their humble beginnings in West Auckland to their current home in the Hawke’s Bay, they’ve built a legacy steeped in tradition and passion. Each bottle carries the essence of those who have shaped its creation, preserving the spirit of their winemaking family through the generations. Selaks’ commitment to quality and excellence has traveled far beyond borders, embraced by wine lovers across the globe.
For more information about Selaks Origins Breeze 5% visit www.selaks.co.nz
Alimetry Secures CPT III Reimbursement Code for the Gastric Alimetry Test and Announces Positive Clinical Study Results
Alimetry, a gastrointestinal medtech and digital health start-up, announced today the creation of a new American Medical Association (AMA) Current Procedural Terminology (CPT) III code for Body Surface Gastric Mapping, which will describe its Gastric Alimetry test.
The new CPT III code highlights the growing recognition of Body Surface Gastric mapping and Gastric Alimetry as a significant advance in the diagnosis and management of chronic gastric conditions, including functional dyspepsia, gastroparesis, and chronic nausea and vomiting syndrome. Together, these disorders affect >10% of the US population.
CEO, Greg O’Grady, a Professor of Surgery and co-founder of Alimetry, said: “Obtaining a CPT III code is a key milestone for Alimetry. Gastric Alimetry is emerging as a next-generation test for patients suffering chronic gastric symptoms, with excellent early adoption in over 30 hospitals and clinics. The new AMA code will accelerate our mission to achieve widespread access for US patients suffering from these disabling disorders.”
The CPT III code comes on the back of Alimetry’s 3rd 510k clearance from the US Food and Drug Administration (FDA) in just 2 years for the Gastric Alimetry System. The latest FDA clearance introduced new features to aid in the diagnosis of gut hypersensitivity and common ‘Gut-Brain-Axis’ disorders, which are often linked to mental wellbeing. Chief Medical Officer Professor Chris Andrews stated: “Gastric symptoms can be complex, and are often a diagnostic challenge. Gastric Aimetry combines a wearable sensor with an App- based digital health profiling tool, providing an increasingly powerful feature set that can greatly simplify the diagnostic process. The cloud-based platform also enables us to rapidly learn and improve test performance based on banked data, with an increasing focus on applications in AI.”
In addition to the new CPT Code, Alimetry also announced positive clinical study results, published this month in the American Journal of Gastroenterology. In the study discussion, the authors concluded that “Gastric Alimetry identified 2.7x more specific patient categories than gastric emptying testing [a standard of care test], with limited overlap between each diagnostic modality, offering a valuable new option in the diagnostic work up of patients with chronic gastroduodenal symptoms”. In addition, Gastric Alimetry data was reported to show “improved correlation with symptoms and psychometrics” compared to existing clinical and research tools.
Gastric Alimetry is commercially available in the United States, the UK and New Zealand. The study article can be accessed in this hyperlink
About Gastric Alimetry
The Gastric Alimetry test measures gastric electrophysiology non-invasively in a clinical setting. Recordings are taken before and after a standard meal, while patients simultaneously log their symptoms into the Gastric Alimetry App. The system performs a high-resolution recording of digestive patterns from the skin surface and delivers clinical reports via the cloud to inform the diagnosis of gastric diseases and support personalized therapy. The Gastric Alimetry system is indicated as an aid to diagnosis of various gastric disorders, including functional dyspepsia, gastroparesis and chronic nausea and vomiting disorders, which affect >10% of the US population and impact billions of dollars in healthcare expenses.
About AMA CPT III Codes
AMA CPT III codes are temporary codes assigned to emerging medical technologies and procedures. These codes facilitate data collection and assessment, aiding in the validation and reimbursement of new services. Obtaining a CPT III code, such as for Alimetry’s Gastric Alimetry test, is a vital step towards recognizing its clinical relevance and supporting its integration into healthcare practices. The new CPT III code number is 0868T and it is effective from July 1, 2024.
About Alimetry
Alimetry is a medtech and digital health start-up focused on improving the care of patients with chronic gastrointestinal symptoms. Spun out of the University of Auckland in 2019 from a centre of excellence in digestive diseases, the company was founded by Professor Gregory O’Grady (CEO) and Dr. Armen Gharibans (CTO), leveraging a decade of award-winning science. Alimetry is dedicated to advancing gastrointestinal health through innovative diagnostic solutions, aiming to enhance the quality of life for patients worldwide. For more information see www.alimetry.com
Contact
Hanie Yee, Chief Commercial Officer, Alimetry Hanie@alimetry.com
NZ +64 (0)21 651226 US +1 (657) 267 1082
New Zealand collaborators reveal innovative gut health product
A Dunedin company, Zestt Wellness, have launched a new gut health product to help counter the damage caused to our digestive system from processed foods and additives. One of the co-founders of Zestt, Dr Anna Campbell, says that damage to our gut health can be associated with the onset of chronic disease.
Campbell, along with fellow founder, Darcy Schack, were driven to create a science-based gut health product that used New Zealand grown ingredients and innovation.
These ingredients include yacon, which according to Campbell is “a superfood due to its amazing prebiotic properties. Yacon provides a form of sugar that our body can’t digest but our gut bacteria can, this helps the growth of good bacteria and inhibits the growth of bad. Clinical trials have shown that yacon can also reduce appetite and help with weight management”. The Zestt team have partnered with Kerikeri organic yacon producer, Marcus van Boxel, and are excited about the availability and quality of yacon in New Zealand.
Knowing the benefits of yacon and finding a local producer were only part of the equation. Through a collaboration with Blenheim based company, Taylor Pass Honey and a Nelson based food scientist, Grant MacDonald, the team have found a way to turn the yacon syrup into a dried product – something that others have not been able to do. A clever bit of local innovation has meant that they have been able to create the new ‘Thrive’ lozenge that has the correct pH and consistency and that also includes other New Zealand ingredients that are good for gut health, such as gold kiwifruit and probiotics from another Dunedin based company, BLIS Technologies.
Creating a quality product from quality ingredients has its challenges. According to Schack “the trick is to combine these ingredients, without losing bioactivity, so a lot of attention to detail and testing needs to happen along the way to insure none of the goodness is lost”.
The inspiration for Zestt Wellness’ products arises from Schack’s personal health battles with Sarcoidosis, a little-known autoimmune disease, which affected his lung, heart and brain functions. Zestt Wellness was established in 2019 and they released their first product EXhale, a lung health and immunity formulation, that year.
Campbell is excited about the new product “launching a product that is based on quality ingredients, quality collaborations, innovation and a bit of Kiwi magic is something that we are proud of; best of all, we know this will make a difference to the health and well-being of some New Zealanders.”
Ends
424 words
About Zestt Wellness
in 2022, Zestt launched their product range in the USA and were named finalists in the Asia Pacific Nutra Ingredients Start Up Company award and winners of the New Zealand China Business Club Innovator award. As a company, they tap into the rich New Zealand science and innovation ecosystem and partner with premium growers throughout the country to develop products with strong science behind them.
To contact Zestt Wellness:
Anna Campbell 027 4861418; anna@zesttwellness.com
Darcy Schack 027 599 2255; darcy@zesttwellness.com
App to help consumers before they get to the Supermarket
As the cost of living crisis bites, a New Zealand company, Sumfood, has launched an app designed to help New Zealander’s save money at the supermarket. The free app lets consumers know which supermarket has the cheapest price, per person, for groceries.
Launched on 1 December, it is hoped that it will provide consumers with a little comfort at the checkout as the holiday season approaches.
Dr Helen Darling of Sumfood believes that the kiwi’s want to help kiwi’s find the best place to shop and, at the same time, drive supermarkets towards fairer and more transparent pricing. To do this, she said, will require innovative people to start using the app, as the amount of data builds, supermarkets will no longer be able to hide behind price differences.
“Anecdotally, we know that where you live has an impact on what you pay at the supermarket – it’s time for some transparency”. Price information is crowd-sourced from motivated consumers.
The app was designed in response to increasing concerns of food price inconsistencies reported through the company’s food reporting tool.
For the last two years the company has collected reports on food issues, with these ranging from concerns about food preparation or hygiene through to contaminants or foreign objects. The company provides a service to consumers that gives them advice on what to do and who to contact.
The new app, FoodSpies.com, uses crowd-sourced data to calculate the average price for a supermarket shop. Shoppers can log on and find the average price, per person, for supermarkets in their region. Data are sourced from shoppers who provide the cost of their shop and the pricing is continuously recalculated so that the most up-to-date information is available.
Darling said that it’s an exciting time to be launching another tool to help consumers, adding that the idea came from her young, motivated team who are committed to making food systems safer and fairer.
Alimetry announces US FDA Clearance for Gastric Alimetry – A Breakthrough Non-Invasive Wearable Device for Gut Diagnostics
Auckland, New Zealand – Alimetry, a medical device and digital healthcare company, today announced it has received US Food and Drug Administration (FDA) clearance for Gastric Alimetry, a pioneering non-invasive medical device for aiding the diagnosis gastric disorders. Alimetry also announced today the launch of Alimetry Inc., a subsidiary based in Minneapolis, MN, that will market and distribute Gastric Alimetry in the United States.
“Gastric Alimetry is an industry-first and genuine breakthrough in gut diagnostics.” said CEO Greg O’Grady, a Professor of Surgery and co-founder of Alimetry. “Alimetry’s unique technology harnesses the power of stretchable electronics, wearables, digital health, and cloud-based analytics to deliver a completely non- invasive solution. We are thrilled to announce FDA’s clearance of Gastric Alimetry, making this new test available to millions of Americans suffering from chronic gastric symptoms”.
The Gastric Alimetry test is performed in a clinical setting. Recordings are taken before and after a meal, while patients simultaneously log their symptoms into the Gastric Alimetry App. The system performs a high-resolution recording of digestive patterns from the skin surface and delivers clinical reports via the cloud to inform the diagnosis of gastric diseases and support personalized therapy.
The system is indicated for common stomach disorders including nausea and vomiting, gastroparesis, and functional dyspepsia, affecting over 8% of the world’s population, and costing billions of dollars in healthcare expenses.1,2 The test is also currently available in the United Kingdom and New Zealand.
“Diagnosing gastric symptoms has been a deeply challenging clinical problem.” Dr. O’Grady said. “Existing tests are frequently unreliable and inconclusive, and patients may undergo months or even years of testing – often costly, invasive, or involving radiation – only to end in confusion and trial-and-error care. Gastric Alimetry is a game-changing tool that will bring improved clarity to field, enabling enhanced clinical outcomes, and safer, more accessible, and less-invasive care.”
Gastric Alimetry is the result of a decade of world-leading science and innovation by an interdisciplinary team of clinicians, engineers, designers and scientists.
“FDA clearance of Gastric Alimetry cements Alimetry’s path to leadership in gastrointestinal wearables and non-invasive diagnostics.” Dr. O’Grady said. “Alimetry has an outstanding pipeline of innovation and this is the first plank in a series of innovative new features and products that stand to transform care in disorders of gastrointestinal function”.
Gastric Alimetry will be available commercially from July 2022.
For more information on Gastric Alimetry visit www.alimetry.com
About Alimetry
Alimetry was spun-out of the University of Auckland in 2019 from a centre of excellence in digestive diseases. The company was founded by Professor Gregory O’Grady, a gastrointestinal surgeon, and Dr. Armen Gharibans, on the background of a decade of award-winning science.
References
- Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, Whitehead WE, Dumitrascu DL, Fang X, Fukudo S, Kellow J. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology. 2021 Jan 1;160(1):99-114.
- Lacy BE, Weiser KT, Kennedy AT, Crowell MD, Talley NJ. Functional dyspepsia: the economic impact to patients. Alimentary pharmacology & therapeutics. 2013 Jul;38(2):170-7.
‘Kia kaha’: PM Ardern Requested to Join PM Albanese in His Calls to Bring Julian Assange Home
A group of lawyers, politicians, journalists and activists known as Aotearoa 4 Assange have written to PM Jacinda Ardern asking her to ‘stand strong’ with new Aussie PM Anthony Albanese, to ‘secure the freedom’ of Australian journalist Julian Assange. According to the letter Assange’s life is in peril and so are the ‘foundations of global democracy’.
A4A spokesperson Matt Ó Branáin says ‘the election of Albanese is a seismic shift’ for the campaign to free Assange, who is currently imprisoned in the UK and fighting extradition to the US. Unlike his predecessor Scott Morrison, Albanese is a member of the Bring Julian Assange Home Parliamentary Group consisting of at least 30 MPs. Albanese has reportedly said ‘enough is enough…I can’t see what’s served by keeping [Assange] incarcerated’.
Green MP and Human Rights lawyer Golriz Ghahraman tweeted ‘the threat to Wikileaks founder Julian Assange’s freedom is a threat to press freedom around the world.’
Assange has been detained in ‘solitary confinement’ for the last 3 years in the UK and a UN Special Rapporteur has said he is being ‘psychologically tortured.’ A letter from hundreds of doctors says he is likely to die soon if not freed.
The US charges ‘criminalise publishing leaked evidence of US state crimes’. International Human Rights groups, including Amnesty International and the Council of Europe’s Commissioner for Human Rights have said the case is a threat to global press freedom.
The letter argues that there is ‘no chance of justice’ if he is extradited to the US as Assange’s ‘legally privileged consultations with his lawyers were spied on’ and the Espionage Act ‘prohibits any public interest defence’.
Ó Branáin says ‘no one can credibly say justice has been seen in the UK extradition trial’. Amnesty International said the UK extradition trial was a ‘circus’. IBAHRI said ‘with this extradition trial, we are witnessing the serious undermining of due processes and the rule of law.’ Applications to monitor the trial from Amnesty International and Reporters Without Borders were declined. A4A’s letter says ‘this is a political case, and political intervention is required’.
UN Special Rapproteur on Torture Nils Melzer says if Assange is extradited to the US he would be detained in ‘conditions that amount to torture’. Ghahraman states that although the UK Magistrate Court has now ordered extradition to be signed ‘the Home Sec must decline’. ‘The UK has an obligation to avoid extradition to a place where he faces ill treatment and torture’. A4A called on Ardern to ‘make representations’ to Ms Patel not to sign the extradition order.
Rt. Hon Helen Clark said ‘you do wonder when the hatchet can be buried with Assange, and not buried in his head by the way?. . . ‘The real issue really is the activities they were exposing, not their actions of exposure.’
Ó Branáin says ‘Australia and New Zealand should call on our allies the US and UK, to end this perilous persecution of a South Pacific journalist, and bring Julian home.’